News
AMGN
343.66
+2.40%
8.05
Viking sends Lilly, Novo lower as obesity drug enters late-stage program
Seeking Alpha · 4h ago
HRTS: Generating Alpha In Obesity Treatment
Tema Obesity & Cardiometabolic ETF (HRTS) is a new actively managed fund focusing on the obesity treatment market. The fund includes a mix of cash flow-positive companies, high-growth companies, and start-ups with promising technology. Consensus price targets for the current portfolio point to 37% upside potential.
Seeking Alpha · 4h ago
QQQ ETF Update, 7/25/2024  
TipRanks · 5h ago
What Lies in Store for Healthcare ETFs in Q2 Earnings?
NASDAQ · 1d ago
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
NASDAQ · 1d ago
Notable Tuesday Option Activity: MEDP, IMVT, AMGN
NASDAQ · 1d ago
3 Stocks That Are Melting Up. Is There Room to Run?
Investorplace · 1d ago
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
NASDAQ · 2d ago
Amgen, Garmin among relative market leaders poised to outperform in coming months: BTIG
Seeking Alpha · 2d ago
TD Cowen Reaffirms Their Buy Rating on Amgen (AMGN)
TipRanks · 2d ago
Amgen (AMGN) Gets a Buy from Piper Sandler
TipRanks · 2d ago
BBH: Buy Rating, As Tech Investors Look Beyond FAANG
VanEck Biotech ETF tracks top U.S.-listed biotech companies, offers exposure to innovative therapies and technologies. Biotechnology sector experiencing exponential growth driven by emerging technologies addressing global challenges. The VanEck biotech ETF (BBH) is under-discovered compared to peers, offers potential for trend change in biotech sector.
Seeking Alpha · 2d ago
Johnson & Johnson: Seriously Undervalued At Peak Pessimism
Johnson & Johnson reported Q2 2024 financial results that exceeded my expectations. The pharmaceutical giant's oncology franchise revenue was up 15.7% year-on-year. The company raised its full-year 2024 operating sales guidance. I continue to cover Johnson & Johnson with a 'Strong Buy' rating. In this article, I focus on the company's pharmaceutical division.
Seeking Alpha · 2d ago
Dow Movers: VZ, AMGN
NASDAQ · 3d ago
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
NASDAQ · 3d ago
Healthcare 2024 Second Half Outlook
Seeking Alpha · 3d ago
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
NASDAQ · 3d ago
Weekly Report: what happened at AMGN last week (0715-0719)?
Weekly Report · 3d ago
10 Best Dividend Growth Stocks to Buy and Hold Forever
Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance. I've selected 10 companies with strong dividend growth records that could amplify your portfolio returns over the long term. Dividend growth stocks typically outperform most other asset classes over five- to 10-year periods. These companies have grown their payouts at a blistering rate.
The Motley Fool · 4d ago
Here are Big Pharma’s leading blockbuster makers
Eli Lilly (LLY) and AstraZeneca (AZN) have emerged joint winners in a list compiled by pharma analytics firm Evaluate. The list ranks companies with the most blockbusters approved over the past decade. The company's blockbusters are expected to generate more than $1B in peak annual sales.
Seeking Alpha · 4d ago
More
Webull provides a variety of real-time AMGN stock news. You can receive the latest news about Amgen Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.